This Article Full Text Full Text (PDF) All Versions of this Article: 42/2/161    most recent 01.HYP.0000079505.25750.11v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mosso, L. Articles by Fardella, C. E. Search for Related Content PubMed PubMed Citation Articles by Mosso, L. Articles by Fardella, C. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB FLUDROCORTISONE Medline Plus Health Information High Blood Pressure

(Hypertension. 2003;42:161.)
© 2003 American Heart Association, Inc.

Scientific Contributions

Primary Aldosteronism and Hypertensive Disease

Lorena Mosso; Cristian Carvajal; Alexis González; Adolfo Barraza; Fernando Avila; Joaquín Montero; Alvaro Huete; Alessandra Gederlini; Carlos E. Fardella

From the Departments of Endocrinology (L.M., C.C., A. González, F.A., C.E.F.), Internal Medicine (A.B., J.M.), Radiology (A.H.), and Public Health (A. Gederlini), Faculty of Medicine, Pontificia Universidad Católica de Chile. Santiago, Chile.

Correspondence to Carlos E. Fardella, MD, Department of Endocrinology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Lira 85, 5 piso, Santiago, Chile. E-mail cfardella{at}med.puc.cl

Recent studies in hypertensive populations that have used the serum aldosterone (SA) to plasma renin activity (PRA) ratio as a screening test have demonstrated a high prevalence of primary aldosteronism (PA). This frequency is higher than that previously described when hypokalemia was used as a screening tool. However, other factors, such as the characteristics of hypertensive disease, could also influence the prevalence of PA. We studied 609 essential hypertensive patients, classified according to the Joint National Committee VI (JNC VI), in 3 different stages depending on the severity of their hypertensive disease. We measured SA and PRA and calculated the SA-PRA ratio for all patients. An SA-PRA ratio >25 was detected in 63 of 609 patients, and the fludrocortisone test confirmed the PA diagnoses in 37 of 609 (6.1%) cases. PA prevalence according to hypertension stage was as follows: stage 1, 6 of 301 cases (1.99%); stage 2, 15 of 187 cases (8.02%); and stage 3, 16 of 121 cases (13.2%). PA patients were slightly younger than the other hypertensive patients (48.4±10.5 vs 53.6±10.2 years; P<0.05). Serum potassium levels were normal in 36 of 37 PA patients; only 1 patient had minor hypokalemia. Computed tomography scans showed bilateral adrenal enlargement in 7 and an adrenal nodule in 2 cases. In summary, we found a high frequency of PA in essential hypertensives classified in stages 2 and 3 according to the JNC VI. The low frequency of computed tomography scan abnormalities and hypokalemia suggests that the diagnosis for most PA patients corresponds to attenuated forms of the disease.

Key Words: hypertension, essential • aldosterone • renin • hypokalemia

This article has been cited by other articles:

				M. J.E. Kempers, J. W.M. Lenders, L. van Outheusden, G. J. van der Wilt, L. J. Schultze Kool, A. R.M.M. Hermus, and J. Deinum Systematic Review: Diagnostic Procedures to Differentiate Unilateral From Bilateral Adrenal Abnormality in Primary Aldosteronism Ann Intern Med, September 1, 2009; 151(5): 329 - 337. [Abstract] [Full Text] [PDF]

				G. J. Becker, T. D. Hewitson, and A. Chrysostomou Aldosterone in clinical nephrology--old hormone, new questions Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2316 - 2321. [Full Text] [PDF]

				F. Hammer and P. M Stewart Investigating hypertension in a young person BMJ, April 6, 2009; 338(apr06_1): b1043 - b1043. [Full Text]

				J. W. Funder, R. M. Carey, C. Fardella, C. E. Gomez-Sanchez, F. Mantero, M. Stowasser, W. F. Young Jr., and V. M. Montori Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3266 - 3281. [Abstract] [Full Text] [PDF]

				D. A. Calhoun, D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation, June 24, 2008; 117(25): e510 - e526. [Abstract] [Full Text] [PDF]

				D. A. Calhoun, D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension, June 1, 2008; 51(6): 1403 - 1419. [Abstract] [Full Text] [PDF]

				L. A. Davies, C. Hu, N. A. Guagliardo, N. Sen, X. Chen, E. M. Talley, R. M. Carey, D. A. Bayliss, and P. Q. Barrett TASK channel deletion in mice causes primary hyperaldosteronism PNAS, February 12, 2008; 105(6): 2203 - 2208. [Abstract] [Full Text] [PDF]

				N. M. Kaplan and D. A. Calhoun Is There an Unrecognized Epidemic of Primary Aldosteronism? (Con) Hypertension, September 1, 2007; 50(3): 454 - 458. [Full Text] [PDF]

				G. E. Umpierrez, P. Cantey, D. Smiley, A. Palacio, D. Temponi, K. Luster, and A. Chapman Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension Diabetes Care, July 1, 2007; 30(7): 1699 - 1703. [Abstract] [Full Text] [PDF]

				S. M. Patel, R. K. Lingam, T. I. Beaconsfield, T. L. Tran, and B. Brown Role of Radiology in the Management of Primary Aldosteronism RadioGraphics, July 1, 2007; 27(4): 1145 - 1157. [Abstract] [Full Text] [PDF]

				D. A. Calhoun Aldosterone and Cardiovascular Disease: Smoke and Fire Circulation, December 12, 2006; 114(24): 2572 - 2574. [Full Text] [PDF]

				D. A. Calhoun Aldosteronism and Hypertension Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1039 - 1045. [Abstract] [Full Text] [PDF]

				P. Mulatero, A. Milan, F. Fallo, G. Regolisti, F. Pizzolo, C. Fardella, L. Mosso, L. Marafetti, F. Veglio, and M. Maccario Comparison of Confirmatory Tests for the Diagnosis of Primary Aldosteronism J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2618 - 2623. [Abstract] [Full Text] [PDF]

				F. Fallo, F. Veglio, C. Bertello, N. Sonino, P. Della Mea, M. Ermani, F. Rabbia, G. Federspil, and P. Mulatero Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 454 - 459. [Abstract] [Full Text] [PDF]

				M. M. H. Kalan, G. Tillou, A. Kulick, C. S. Wilcox, and A. I. Garcia Performing Laparoscopic Adrenalectomy Safely Arch Surg, November 1, 2004; 139(11): 1243 - 1247. [Full Text] [PDF]

				F. H. Perschel, R. Schemer, L. Seiler, M. Reincke, J. Deinum, C. Maser-Gluth, D. Mechelhoff, R. Tauber, and S. Diederich Rapid Screening Test for Primary Hyperaldosteronism: Ratio of Plasma Aldosterone to Renin Concentration Determined by Fully Automated Chemiluminescence Immunoassays Clin. Chem., September 1, 2004; 50(9): 1650 - 1655. [Abstract] [Full Text] [PDF]

				P.-F. Plouin, L. Amar, and G. Chatellier Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension Nephrol. Dial. Transplant., April 1, 2004; 19(4): 774 - 777. [Full Text] [PDF]